QIAGEN EBITDA 2010-2022 | QGEN

QIAGEN annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • QIAGEN EBITDA for the quarter ending March 31, 2022 was $0.268B, a 18.05% increase year-over-year.
  • QIAGEN EBITDA for the twelve months ending March 31, 2022 was $0.918B, a 24.85% increase year-over-year.
  • QIAGEN 2021 annual EBITDA was $0.877B, a 38.43% increase from 2020.
  • QIAGEN 2020 annual EBITDA was $0.634B, a 157.54% increase from 2019.
  • QIAGEN 2019 annual EBITDA was $0.246B, a 51.61% decline from 2018.
QIAGEN Annual EBITDA
(Millions of US $)
2021 $877
2020 $634
2019 $246
2018 $509
2017 $395
2016 $332
2015 $391
2014 $378
2013 $263
2012 $368
2011 $267
2010 $331
2009 $301
QIAGEN Quarterly EBITDA
(Millions of US $)
2022-03-31 $268
2021-12-31 $232
2021-09-30 $193
2021-06-30 $224
2021-03-31 $227
2020-12-31 $224
2020-09-30 $107
2020-06-30 $178
2020-03-31 $126
2019-12-31 $143
2019-09-30 $-141
2019-06-30 $132
2019-03-31 $113
2018-12-31 $148
2018-09-30 $134
2018-06-30 $117
2018-03-31 $109
2017-12-31 $105
2017-09-30 $122
2017-06-30 $84
2017-03-31 $84
2016-12-31 $66
2016-09-30 $107
2016-06-30 $87
2016-03-31 $72
2015-12-31 $115
2015-09-30 $101
2015-06-30 $89
2015-03-31 $86
2014-12-31 $88
2014-09-30 $102
2014-06-30 $97
2014-03-31 $91
2013-12-31 $88
2013-09-30 $85
2013-06-30 $15
2013-03-31 $74
2012-12-31 $103
2012-09-30 $89
2012-06-30 $94
2012-03-31 $82
2011-12-31 $27
2011-09-30 $77
2011-06-30 $85
2011-03-31 $77
2010-12-31 $89
2010-09-30 $50
2010-06-30 $43
2010-03-31 $79
2009-12-31 $69
2009-09-30 $53
2009-06-30 $51
2009-03-31 $68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.982B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00